The Glooko ROI Calculator

Telehealth and remote patient monitoring have emerged as patient-centered strategies to deliver diabetes support and education. Through mobile and cloud technology, organizations can provide timely and convenient support to their diabetes population in between visits.

Enabling nurses, coaches, or other care team members to remotely track at-risk people with diabetes (PWDs), quickly identify trends and out-of-range blood glucose (BG) readings, and provide support through a diabetes program, can ultimately improve outcomes at a lower cost. As a result, PWDs become engaged with their health and are able to obtain individualized advice for lasting impact. They are also able to make accurate connections between their lifestyle behavior and BG data, thus creating opportunities for behavior change.

The Glooko diabetes management platform for remote monitoring aims to improve health outcomes and reduce diabetes costs through diabetes data unification and population management tools. FDA-cleared and HIPAA-compliant, Glooko integrates with a majority of the world’s most popular BG meters, insulin pumps, continuous glucose monitors, fitness trackers and mobile devices already used by PWDs. Glooko automatically makes uploaded BG data accessible to healthcare systems, payers, and employers making it easy for the PWD to learn from and share their data. This allows care teams to make timely, individualized diabetes treatment decisions based on how the PWD’s lifestyle decisions impacts their glycemic control and ultimately their health.  

The Glooko ROI Calculator is an interactive tool that tells you how much your organization can save when deploying Glooko among your diabetes population. It takes into account how much it would cost for your organization to deploy Glooko and the resulting additional diabetes medical cost reduction. By telling us a couple of details about your diabetes patient population and sharing your remote monitoring goals, we will calculate your organization’s return on investment.

To calculate your return on investment when using Glooko, several studies have been used to determine the appropriate cost reduction per level of  remote monitoring intervention. The studies used to demonstrate diabetes cost savings linked to remote monitoring include:

1. Type 2 diabetes affects 7.8% of the US population, yet only 7% of that population meets guidelines for BG control. Stamp and colleagues examined the effects of a telehealth program for urban-dwelling participants with Type 2 diabetes who exhibited poor BG control. Participants uploaded diabetes data remotely to a secure website, which automatically shared the data to a nurse-led team. Nurses were able to identify when participants were at-risk and provided timely and individualized feedback over the phone. As a result, participants showed a statistically and clinically significant improvement with an HbA1c reduction of -1.8 to -2.2%, depending on the level of participant engagement.(1)

For a diabetes population of 15,000 participants, deploying the interventions described in the Stamp study would lead to a cost savings of $903,040.00 or a 7.8:1 ROI. 

2. PWDs who are engaged early in their health and who continue to remain active have better clinical outcomes compared to unengaged PWDs. Although the benefits of diabetes self-management are well known, the best health outcome is achieved when the care team is engaged with the patient and meaningfully uses diabetes data. Jethwani and colleagues evaluated PWDs adoption and engagement of a web-based diabetes self-management program. Participants uploaded diabetes data to a secure website, which automatically shared their data to their care team. Glucose readings that were not within the participant’s targeted range were flagged for the provider. Results of the study showed that engaged participants, as defined by their number of readings per upload and frequency of upload, displayed an average HbA1c drop of -1.5%. Those who were non-engaged only had an average HbA1c decrease of -0.4%. Still even, participants with more engaged providers had a better HbA1c change, -1.39% compared to -0.87%.(2)

For a diabetes population of 15,000 participants, deploying the interventions described in the Jethwani study would lead to a cost savings of $303,941.00 or a 3.2:1 ROI. 

3. Non-adherence to a diabetes treatment plan is linked to poor health outcomes, progression of disease symptoms and an average increase in medical costs of $2,000 per patient per year(3). Zullig and colleagues reviewed several studies that effectively improved medication adherence among a diabetes population. In many of these studies, participants were provided with real-time monitoring devices and reminders to stay on top of their care routine. For every 10% improvement in treatment adherence, there was a 6% reduction in diabetes-related costs.(4) For PWDs, this means that improving medication adherence could result in an estimated cost savings for the US health care system ranging from $661 million to $1.16 billion.(5)

For a diabetes population of 15,000 participants, deploying the interventions described in the Zullig study would lead to a cost savings of $267,258.00 or a 2.9:1 ROI. 

4. Tsang and colleagues examined the effects of a computerized diabetes monitoring system focused on dietary habits. In the study, participants manually recorded their BG and carb intake in a hand-held electronic diary in which the data was transmitted to their care team. As a result, participants received immediate feedback about the contents of their meal. Participants showed a significant improvement in glycemic control with an average HbA1c reduction of -0.825%. Additionally, 95% of the participants found the system easy to use, showing that the diabetes monitoring system was feasible and cost-effective.(6)

For a diabetes population of 15,000 participants, deploying the interventions described in the Tsang study would lead to a cost savings of $191,610.00 or a 2.3:1 ROI. 

5. PWDs typically spend no more than a few hours a year in a clinical setting, yet their health outcomes are mainly determined by the choices they make outside of the clinic. Mobile phones are a promising platform for empowering patient engagement because the majority of patients own and regularly use a mobile phone. In fact, text messaging allows PWDs to send and receive health information that is delivered quickly and is targeted for their individual needs. Nundy and colleagues examined the impact of a mobile health program. In addition to improvements in glycemic control and high patient satisfaction, the study results showed a statistically significant improvement with an average HbA1c reduction of -0.7% and a net cost savings of 8.8%.(7)

For a diabetes population of 15,000 participants, deploying the interventions described in the Nundy study would lead to a cost savings of $154,166.00 or a 2.0:1 ROI. 

6. Bashshur and colleagues assessed scientific evidence for telemedicine interventions in the management of diabetes. Participants were supplied with an electronic diabetes management system to allow them to share their data remotely with their care team. This allowed the participant and their healthcare provider to send and receive text messages related to the participant’s BG trends. From the literature review, they found sufficient evidence to confirm the positive effects of telemonitoring for PWDs, including improved BG control, reduced body weight and increased physical exercise. Additionally, participants showed a statistically significant BG improvement with an average HbA1c reduction of -0.5%.(8)

For a diabetes population of 15,000 participants, deploying the interventions described in the Bashshur study would lead to a cost savings of $32,474.00 or a 1.1:1 ROI. 

Each of these six studies is used in an online, interactive Glooko ROI Calculator to determine the scale of the return on investment your organization can receive when using Glooko.

Sources:

(1) Stamp KD, Allen NA, Lehrer S, et al., Telehealth Program for Medicaid Patients with Type 2 Diabetes Lowers Hemoglobin A1c, Journal of Managed Care Medicine, 2012;15(4):3-10.

(2) Jethwani K, Ling E, Mohammed M, et al., Diabetes Connect: An Evaluation of Patient Adoption and Engagement in a Web-Based Remote Glucose Monitoring Program, Journal of Diabetes Science and Technology, 2012;6(6):1328-1336.

(3) Sokol MC, McGuigan KA, Verbrugge RR, et al., Impact of Medication Adherence on Hospitalization Risk and Healthcare Cost, Medical Care, 2005;43(6):521-530.

(4,5) Zullig LL, Gellad WF, Moaddeb J, et al., Improving Diabetes Medication Adherence: Successful, Scalable Interventions, Patient Preference and Adherence, 2015:9:139-149.

(6) Tsang MW, Mok M, Kam G, et al., Improvement in Diabetes Control with a Monitoring System Based on a Hand-Held, Touch-Screen Electronic Diary, Journal of Telemedicine and Telecare, 2001;7(1):47-50.

(7) Nundy S, Dick JJ, Chou CH, et al., Mobile Phone Diabetes Project Led to Improved Glycemic Control and Net Savings for Chicago Plan Participants, Health Affairs, 2014;33(2):265-272.

(8) Bashshur RL, Shannon GW, Smith BR, et al., The Empirical Evidence for the Telemedicine Intervention in Diabetes Management, Telemedicine and e-Health, 2015;21(5):321-356.

 

Sidhtara Tep

Sidhtara is a Marketing Manager at Glooko. She's interested in the intersection of technology and healthcare and how together, they can bring positive and sustainable change to people's lives.